Arcus Biosciences, Inc. Accrued Liabilities, Current
Arcus Biosciences, Inc. (RCUS) had Accrued Liabilities, Current of $20.53 million as of 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2022-11-02
- 2022-09-30: Accrued Liabilities, Current $20.53M.
- 2022-06-30: Accrued Liabilities, Current $14.44M.
- 2022-03-31: Accrued Liabilities, Current $16.20M.
- 2021-12-31: Accrued Liabilities, Current $24.18M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2022-09-30 | $20.53M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $14.44M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $16.20M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $24.18M 10-Q · filed 2022-11-02 | |
| 2021-09-30 | $14.63M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $9.71M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.54M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $9.54M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $7.50M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.61M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $10.17M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $4.95M 10-K · filed 2021-02-25 | $9.52M 10-K · filed 2020-03-05 |
| 2019-09-30 | $9.66M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $15.55M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $7.63M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $6.02M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $6.67M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $4.34M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $3.61M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.14M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |